Published in Hematology Week, April 26th, 2010
The oral presentation describes efficacy of the company's first-in-human Btk inhibitor PCI-32765 in a mouse model of pancreatic cancer (Soucek et al). Two other presentations describe the discovery of drug synergy with the company's HDAC inhibitor, PCI-24781 and the drug bortezomib in neuroblastoma (Currier et al), or with inhibitors of LSD1 in glioblastoma (Singh et al). An additional presentation describes preclinical development of the company's novel...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week